MedPath

FDA Approves Labeling Change for Biktarvy Based on Clinical Data

• The FDA has approved a labeling change for Biktarvy, an HIV-1 treatment, based on new clinical data. • This approval reflects ongoing updates to the drug's efficacy and safety profile as new data emerges. • Biktarvy, developed by Gilead Sciences, continues to be a key therapeutic option in HIV management. • The labeling changes are based on supplemental applications reviewed and approved by the FDA.

The U.S. Food and Drug Administration (FDA) has approved a supplemental application for Biktarvy, leading to updated labeling based on the latest clinical data. This approval, issued to Gilead Sciences, reflects the FDA's ongoing review and adaptation of drug labels to incorporate new efficacy and safety information.
The FDA's decision is based on a series of supplemental applications (SUPPL) submitted by Gilead Sciences. These applications included changes related to efficacy, new indications, and patient populations. The updates ensure that healthcare providers have access to the most current information regarding Biktarvy's use in treating HIV-1 infection.
Biktarvy is a fixed-dose combination drug containing bictegravir, emtricitabine, and tenofovir alafenamide. It is used for the treatment of HIV-1 infection in adults and children of certain weight and age. The drug works by inhibiting the viral enzyme integrase, thereby preventing the virus from replicating in human cells.
The continuous updates to Biktarvy's label demonstrate the commitment of both Gilead Sciences and the FDA to providing healthcare professionals with the most accurate and relevant information. These labeling changes, driven by clinical data, are crucial for optimizing treatment strategies and improving patient outcomes in the management of HIV-1.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Requires Label Update for Agios Pharmaceuticals' Pyrukynd

The US Food and Drug Administration has mandated Agios Pharmaceuticals to update the label of its hemolytic anemia drug, Pyrukynd, to include the risk of liver injury. This move comes amidst other significant developments in the pharmaceutical sector, including positive Phase II results from Oculis Holdings and a licensing deal between Climb Bio and Mabworks Biotech.

Latest Updates on FDA Approvals and Processes

The Food and Drug Administration (FDA) continues to oversee the approval process for new products, drugs, therapies, and treatments, with updates on applications, safety alerts, and more.

FDA Approves Alhemo for Hemophilia and alfapump System for Liver Cirrhosis

The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent bleeding episodes in hemophilia A and B patients with inhibitors.
Recommended dosing for Alhemo is available in the prescribing information, with common adverse reactions including injection site reactions and hives.

Gilead's Trodelvy Receives FDA Breakthrough Therapy Designation for SCLC; Seladelpar Recommended for EU Approval

The FDA granted Breakthrough Therapy Designation to Gilead's Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy, based on promising results from the TROPiCS-03 study.
Gilead will collaborate with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets, leveraging Terray's tNova platform.

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

The FDA has approved updated labeling for fludarabine phosphate injection under Project Renewal, an initiative focused on modernizing oncology drug labels.
The updated label provides clearer guidance for using fludarabine phosphate in combination with cyclophosphamide and rituximab for B-cell CLL treatment.

FDA Grants Fast Track and Rare Pediatric Disease Designations to Gildeuretinol for Stargardt Disease

The FDA has granted rare pediatric disease and fast track designations to gildeuretinol, an oral therapy being developed by Alkeus Pharmaceuticals for Stargardt disease.
Clinical data from the TEASE-1 study showed gildeuretinol slowed the growth rate of atrophic retinal lesions by 21.6% compared to placebo over 24 months.

PharmaTher on Track for Ketamine FDA Resubmission, Anticipates Q2 2025 Approval

PharmaTher is set to resubmit its Ketamine New Drug Application to the FDA by the end of February 2025, addressing minor deficiencies outlined in the FDA's response letter.
The FDA's feedback indicated that the resubmission will be treated as a minor amendment, focusing on drug substance, product manufacturing, and microbiology clarifications.

Gilead Presents New HIV Treatment Data, Including Long-Term Biktarvy Results and Novel Regimens

Four-year data from the BICSTaR study confirms Biktarvy's sustained efficacy and safety in diverse HIV patients, showing high rates of virologic suppression and improved patient outcomes.
ROSETTA registry analysis reveals distinct resistance pathways for integrase strand transfer inhibitors (INSTIs) based on prior exposure, informing future INSTI use in HIV treatment.

FDA Accepts Rivoceranib and Camrelizumab Combination for Liver Cancer

The FDA has accepted the resubmitted NDA for rivoceranib combined with camrelizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (uHCC).
The application is supported by the Phase 3 CARES-310 trial, which demonstrated a median overall survival of 23.8 months, the longest in a global Phase 3 uHCC trial.

FDA Approves Biktarvy Label Update With Data for Pregnant Adults with HIV

The FDA has approved an updated label for Biktarvy, including data supporting its safety and efficacy for treating pregnant individuals with HIV-1 who have suppressed viral loads. This update is based on Study 5310, which evaluated Biktarvy's pharmacokinetics, safety, and efficacy during pregnancy and postpartum.

Reference News

[1]
FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC - Quantisnow
quantisnow.com · Oct 22, 2024

Updates to drug labeling include efficacy changes with clinical data, new indications, and patient population expansions...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy